Milestone Pharmaceuticals (NASDAQ:MIST) Lowered to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a hold rating to a sell rating in a report published on Saturday morning, Zacks.com reports.

According to Zacks, “Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company’s lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montréal, Canada. “

Separately, ValuEngine raised Milestone Pharmaceuticals from a hold rating to a buy rating in a report on Tuesday, October 1st. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. Milestone Pharmaceuticals presently has an average rating of Buy and an average target price of $30.10.

Shares of Milestone Pharmaceuticals stock opened at $21.25 on Friday. Milestone Pharmaceuticals has a fifty-two week low of $15.09 and a fifty-two week high of $27.95. The company has a 50-day moving average price of $20.31.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Tuesday, August 13th. The company reported ($1.04) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.56). On average, equities analysts anticipate that Milestone Pharmaceuticals will post -3.32 EPS for the current year.

In other Milestone Pharmaceuticals news, major shareholder Stonepine Capital, L.P. acquired 100,000 shares of the firm’s stock in a transaction that occurred on Friday, October 11th. The stock was acquired at an average cost of $0.63 per share, with a total value of $63,000.00. Also, major shareholder Rtw Investments, Lp acquired 5,487 shares of the firm’s stock in a transaction that occurred on Tuesday, October 15th. The stock was acquired at an average cost of $18.95 per share, with a total value of $103,978.65. Insiders purchased a total of 113,637 shares of company stock valued at $311,967 over the last three months.

Hedge funds have recently modified their holdings of the stock. Tower Research Capital LLC TRC acquired a new stake in Milestone Pharmaceuticals in the second quarter worth approximately $51,000. Landscape Capital Management L.L.C. acquired a new stake in Milestone Pharmaceuticals in the second quarter worth approximately $459,000. Pentwater Capital Management LP acquired a new stake in Milestone Pharmaceuticals in the second quarter worth approximately $679,000. VHCP Management II LLC acquired a new stake in Milestone Pharmaceuticals in the second quarter worth approximately $4,033,000. Finally, Zimmer Partners LP acquired a new stake in Milestone Pharmaceuticals in the second quarter worth approximately $4,344,000. 53.41% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Recommended Story: Oversold

Get a free copy of the Zacks research report on Milestone Pharmaceuticals (MIST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.